Rich S - Search Results

1

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.

McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S; Treprostinil Study Group. McLaughlin VV, et al. Among authors: rich s. J Cardiovasc Pharmacol. 2003 Feb;41(2):293-9. doi: 10.1097/00005344-200302000-00019. J Cardiovasc Pharmacol. 2003. PMID: 12548091 Clinical Trial.

2

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

McLaughlin VV, Shillington A, Rich S. McLaughlin VV, et al. Among authors: rich s. Circulation. 2002 Sep 17;106(12):1477-82. doi: 10.1161/01.cir.0000029100.82385.58. Circulation. 2002. PMID: 12234951 Clinical Trial.

3

Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension.

Rich S, Shillington A, McLaughlin V. Rich S, et al. Am J Cardiol. 2003 Dec 1;92(11):1366-8. doi: 10.1016/j.amjcard.2003.08.034. Am J Cardiol. 2003. PMID: 14636926

4

Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G; Treprostinil Study Group. Oudiz RJ, et al. Among authors: rich s. Chest. 2004 Aug;126(2):420-7. doi: 10.1378/chest.126.2.420. Chest. 2004. PMID: 15302727 Clinical Trial.

5

Pulmonary hypertension.

McLaughlin VV, Rich S. McLaughlin VV, et al. Among authors: rich s. Curr Probl Cardiol. 2004 Oct;29(10):575-634. doi: 10.1016/j.cpcardiol.2004.04.001. Curr Probl Cardiol. 2004. PMID: 15494704 Review.

6

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.

Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Gomberg-Maitland M, et al. Among authors: rich s. Am J Cardiol. 2005 Nov 1;96(9):1334-6. doi: 10.1016/j.amjcard.2005.06.083. Epub 2005 Sep 16. Am J Cardiol. 2005. PMID: 16253609 Clinical Trial.

7

Medical & surgical approaches to pulmonary hypertension.

McLaughlin VV, Rich S. McLaughlin VV, et al. Among authors: rich s. Compr Ther. 1997 Sep;23(9):612-6. Compr Ther. 1997. PMID: 9285162 Review.

8

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

McLaughlin VV, Genthner DE, Panella MM, Rich S. McLaughlin VV, et al. Among authors: rich s. N Engl J Med. 1998 Jan 29;338(5):273-7. doi: 10.1056/NEJM199801293380501. N Engl J Med. 1998. PMID: 9445406 Free article. Clinical Trial.

9

Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation.

Rich S, McLaughlin VV. Rich S, et al. Semin Thorac Cardiovasc Surg. 1998 Apr;10(2):135-8. doi: 10.1016/s1043-0679(98)70007-3. Semin Thorac Cardiovasc Surg. 1998. PMID: 9620461 Review.

10

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

Rich S, McLaughlin VV. Rich S, et al. J Am Coll Cardiol. 1999 Oct;34(4):1184-7. doi: 10.1016/s0735-1097(99)00320-4. J Am Coll Cardiol. 1999. PMID: 10520810 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,625 results

Search Page

Filters